HIV therapeutic vaccine enhances non-exhausted CD4
Peptide vaccines
Viral infection
Journal
NPJ vaccines
ISSN: 2059-0105
Titre abrégé: NPJ Vaccines
Pays: England
ID NLM: 101699863
Informations de publication
Date de publication:
2019
2019
Historique:
received:
14
12
2018
accepted:
26
04
2019
entrez:
25
6
2019
pubmed:
25
6
2019
medline:
25
6
2019
Statut:
epublish
Résumé
VAC-3S is a therapeutic vaccine comprising a highly conserved HIV-gp41 motif coupled with the CRM197 carrier protein. High levels of anti-3S antibodies (Abs) have been associated with improved protection of CD4
Identifiants
pubmed: 31231551
doi: 10.1038/s41541-019-0117-5
pii: 117
pmc: PMC6546693
doi:
Types de publication
Journal Article
Langues
eng
Pagination
25Commentaires et corrections
Type : ErratumIn
Déclaration de conflit d'intérêts
Competing interestsV.V. and P.D. are founders of InnaVirVax and consultants for Minka Tx. B.C. is consultant for Minka Tx. S.G. has been consultant for InnaVirVax. D.J. is Chief Operative Officer of Minka Tx. The remaining authors declare no competing interests.
Références
Clin Immunol. 1999 Jun;91(3):283-95
pubmed: 10370373
Proc Natl Acad Sci U S A. 2005 Aug 2;102(31):10981-6
pubmed: 16046540
Nat Med. 2006 Oct;12(10):1198-202
pubmed: 16917489
Nature. 2006 Sep 21;443(7109):350-4
pubmed: 16921384
AIDS. 2006 Sep 11;20(14):1795-804
pubmed: 16954720
Blood. 2007 Aug 15;110(4):1207-14
pubmed: 17513617
J Immunol. 2007 Aug 1;179(3):1979-87
pubmed: 17641065
Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):2100-4
pubmed: 18234855
Clin Infect Dis. 2009 Mar 15;48(6):787-94
pubmed: 19193107
AIDS. 2009 Jun 1;23(9):1077-87
pubmed: 19424050
N Engl J Med. 2009 Oct 15;361(16):1548-59
pubmed: 19828532
Proc Natl Acad Sci U S A. 2010 Jun 8;107(23):10632-7
pubmed: 20498045
Annu Rev Pathol. 2011;6:223-48
pubmed: 21034222
Trends Immunol. 2011 Mar;32(3):131-7
pubmed: 21317040
Blood. 2011 Jul 28;118(4):965-74
pubmed: 21652684
Hum Vaccin. 2011 Aug;7(8):811-27
pubmed: 21817854
J Acquir Immune Defic Syndr. 2012 Nov 1;61(3):403-5
pubmed: 22732471
J Exp Med. 2012 Jul 30;209(8):1391-5
pubmed: 22851641
Vaccine. 2012 Nov 6;30(48):6883-91
pubmed: 22989687
N Engl J Med. 2013 Feb 7;368(6):551-60
pubmed: 23388006
Vaccine. 2013 Jun 7;31(25):2756-61
pubmed: 23583812
Immunol Rev. 2013 Jul;254(1):54-64
pubmed: 23772614
Blood. 2013 Oct 24;122(17):2935-42
pubmed: 23958951
Lancet. 2014 Jul 19;384(9939):241-8
pubmed: 25042234
PLoS Pathog. 2014 Nov 20;10(11):e1004521
pubmed: 25412359
JAMA Intern Med. 2015 Jan;175(1):88-99
pubmed: 25419650
AIDS. 2016 Jan;30(2):221-30
pubmed: 26684819
Clin Exp Immunol. 2016 Jul;185(1):1-21
pubmed: 26919392
Oncotarget. 2016 Jun 21;7(25):38946-38958
pubmed: 26950274
PLoS Pathog. 2016 Jul 14;12(7):e1005761
pubmed: 27415008
AIDS. 2016 Sep 24;30(15):2299-302
pubmed: 27428742
Lancet HIV. 2017 Jul;4(7):e295-e302
pubmed: 28479492
Ann Oncol. 2018 Feb 1;29(2):517-518
pubmed: 29206889
Trends Immunol. 2018 Jun;39(6):460-472
pubmed: 29496432
J Int AIDS Soc. 2018 Jul;21(7):e25144
pubmed: 29987877
Lancet. 2018 Aug 25;392(10148):685-697
pubmed: 30049419
AIDS. 2018 Oct 23;32(16):2291-2299
pubmed: 30096071